JP7557522B2 - Ｃｄ７３阻害剤 - Google Patents

Ｃｄ７３阻害剤 Download PDF

Info

Publication number
JP7557522B2
JP7557522B2 JP2022502302A JP2022502302A JP7557522B2 JP 7557522 B2 JP7557522 B2 JP 7557522B2 JP 2022502302 A JP2022502302 A JP 2022502302A JP 2022502302 A JP2022502302 A JP 2022502302A JP 7557522 B2 JP7557522 B2 JP 7557522B2
Authority
JP
Japan
Prior art keywords
optionally substituted
pharma
alkyl
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540890A (ja
JP2022540890A5 (enExample
Inventor
ドュ，シャオフイ
エクステロウィッツ，ジョン
アール． ファンティン，ヴァレリア
サン，ダチン
イェ，チョウピン
ムーア，ジャレド
ザヴォロティンスカヤ，タチアナ
アール． ブランク，ブライアン
カワイ，ヒロユキ
イェ，チェン－ホン
リュウ，ヨサップ
ウー，ケジア
ファム，ジョニー
Original Assignee
オリック ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリック ファーマシューティカルズ，インク． filed Critical オリック ファーマシューティカルズ，インク．
Publication of JP2022540890A publication Critical patent/JP2022540890A/ja
Publication of JP2022540890A5 publication Critical patent/JP2022540890A5/ja
Application granted granted Critical
Publication of JP7557522B2 publication Critical patent/JP7557522B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022502302A 2019-07-16 2020-07-15 Ｃｄ７３阻害剤 Active JP7557522B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962874533P 2019-07-16 2019-07-16
US62/874,533 2019-07-16
US201962927974P 2019-10-30 2019-10-30
US62/927,974 2019-10-30
US202062987653P 2020-03-10 2020-03-10
US62/987,653 2020-03-10
US202063049927P 2020-07-09 2020-07-09
US63/049,927 2020-07-09
PCT/US2020/042183 WO2021011689A1 (en) 2019-07-16 2020-07-15 Cd73 inhibitors

Publications (3)

Publication Number Publication Date
JP2022540890A JP2022540890A (ja) 2022-09-20
JP2022540890A5 JP2022540890A5 (enExample) 2023-05-12
JP7557522B2 true JP7557522B2 (ja) 2024-09-27

Family

ID=74209960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502302A Active JP7557522B2 (ja) 2019-07-16 2020-07-15 Ｃｄ７３阻害剤

Country Status (4)

Country Link
US (1) US12544391B2 (enExample)
EP (1) EP3999517A4 (enExample)
JP (1) JP7557522B2 (enExample)
WO (1) WO2021011689A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
IL292570B2 (en) 2019-10-30 2024-04-01 Oric Pharmaceuticals Inc Cd73 inhibitors
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20250004779A (ko) 2022-04-13 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암을 치료하기 위한 병용 요법
WO2025096605A1 (en) * 2023-10-31 2025-05-08 Oric Pharmaceuticals, Inc. Cd73 inhibitor and anti-cd38 agent combination therapy
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118359622B (zh) * 2024-04-16 2025-08-26 上海陶术生物科技股份有限公司 加利司伟中间体的制备方法
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
CN119552122B (zh) * 2025-01-27 2025-05-09 北京悦康科创医药科技股份有限公司 5'-磷酸酯修饰核苷及其制备方法与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019129059A1 (zh) 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
EP3971210A1 (en) 2014-12-12 2022-03-23 2seventy bio, Inc. Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
SG11201805506YA (en) 2016-01-08 2018-07-30 Arcus Biosciences Inc Modulators of 5'-nucleotidase, ecto and the use thereof
TWI767937B (zh) 2016-09-09 2022-06-21 美商卡利泰拉生物科技公司 外核苷酸酶抑制劑及其使用方法
JP7150712B2 (ja) 2016-11-18 2022-10-11 アーカス バイオサイエンシズ インコーポレイティド Ｃｄ７３媒介免疫抑制の阻害剤
CA3047988A1 (en) 2016-12-22 2018-06-28 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
WO2018208980A1 (en) 2017-05-10 2018-11-15 Oric Pharmaceuticals, Inc. Cd73 inhibitors
CN112423764A (zh) 2018-04-30 2021-02-26 欧瑞克制药公司 Cd73抑制剂
WO2019232319A1 (en) * 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
CA3143496A1 (en) 2019-06-20 2020-12-24 Antengene Therapeutics Limited Ectonucleotidase inhibitors and methods of use thereof
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
IL292570B2 (en) 2019-10-30 2024-04-01 Oric Pharmaceuticals Inc Cd73 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
WO2019129059A1 (zh) 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用

Also Published As

Publication number Publication date
EP3999517A4 (en) 2023-07-12
JP2022540890A (ja) 2022-09-20
US20220331343A1 (en) 2022-10-20
EP3999517A1 (en) 2022-05-25
US12544391B2 (en) 2026-02-10
WO2021011689A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
US12544391B2 (en) CD73 inhibitors
JP7617890B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
AU2023263567B2 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
CA2921982C (en) Novel cytotoxic agents for conjugation of drugs to cell binding molecule
CN115175735A (zh) 抗病毒化合物
CA3191842A1 (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
CN116283647A (zh) 整合应激通路的前药调节剂
CN103827108B (zh) 丙型肝炎病毒抑制剂
JP2020508310A (ja) インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
JP2013533317A (ja) Ｃ型肝炎ウイルス阻害剤
CN112888696A (zh) 外核苷酸酶抑制剂及其使用方法
TWI716976B (zh) 高活性sting蛋白激動劑
CA3087727A1 (en) Glucopyranosyl derivative and use thereof
TW202332429A (zh) 治療性化合物及其使用方法
CN104292125B (zh) 萘衍生物及其在药物上的应用
US9561212B2 (en) Hepatitis C virus inhibitors
CN106573927B (zh) 氧杂环庚烷-2-基-吡唑-4-基-杂环基-甲酰胺化合物和使用方法
CN113563246B (zh) 取代的氮杂五元环类衍生物及其在药物中的应用
RU2799446C2 (ru) Ингибиторы протеин-тирозинфосфатазы и способы их применения
HK40083235A (en) Antiviral compounds
HK40049700A (en) Ectonucleotidase inhibitors and methods of use thereof
HK40047065A (en) Antiproliferation compounds and uses thereof
HK40047065B (en) Antiproliferation compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240913

R150 Certificate of patent or registration of utility model

Ref document number: 7557522

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150